Entrada Therapeutics (TRDA) Net Margin (2023 - 2026)
Entrada Therapeutics' Net Margin was -4762.03% in Q2 2026, down 2551.62 percentage points from -2210.41% a year earlier and down 222.94 percentage points from the prior quarter.
Powered by 
Analysis
Entrada Therapeutics (TRDA) Net Margin (2023 - 2026) Analysis & Trends
On a trailing twelve-month basis, Entrada Therapeutics' Net Margin was -3537.73% through Jun 30, 2026, down 3445.43 percentage points year-over-year; for FY2025, it was -565.48%, down 596.61 percentage points from FY2024.
- In earlier years, Net Margin was 31.13% in FY2024 (+36.32 pp) and -5.18% in FY2023.
- The Q2 2026 figure marks the lowest quarterly Net Margin in data going back to Q1 2023.
- Compared with a year earlier, Net Margin has declined for six straight quarters, with an average year-over-year change of -1900.83 percentage points over the last eight quarters.
- The best year-over-year quarter for Net Margin over five years was Q2 2024 (a gain of 200.81 percentage points); the worst was Q1 2026 (a drop of 4454.70 percentage points).
- Per Business Quant data, TRDA's Net Margin in the three quarters before Q2 2026 was -4539.09% (Q1 2026), -3014.93% (Q4 2025) and -2734.45% (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 655.56 Bn | 574.09 Bn | 17.26 Bn | 21.86% |
| 2 | AbbVie | 470.94 Bn | 444.10 Bn | 12.70 Bn | 21.27% |
| 3 | Merck | 367.14 Bn | 321.57 Bn | 12.21 Bn | -8.04% |
| 4 | Novartis Ag | 280.33 Bn | 236.20 Bn | 11.24 Bn | 22.61% |
| 5 | Astrazeneca | 257.78 Bn | 231.34 Bn | 12.86 Bn | 18.81% |
| 6 | Amgen | 226.04 Bn | 181.44 Bn | 7.24 Bn | 23.62% |
| 7 | Gilead Sciences | 188.89 Bn | 163.01 Bn | 6.22 Bn | -134.51% |
| 8 | Pfizer | 163.75 Bn | 110.70 Bn | 10.94 Bn | -1.65% |
| 9 | Vertex Pharmaceuticals | 133.68 Bn | 105.69 Bn | 2.84 Bn | 32.99% |
| 10 | Entrada Therapeutics | 242.19 Mn | 242.19 Mn | - | -4,762.03% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -4,762.03% |
| Mar 31, 2026 | -4,539.09% |
| Dec 31, 2025 | -3,014.93% |
| Sep 30, 2025 | -2,734.45% |
| Jun 30, 2025 | -2,210.41% |
| Mar 31, 2025 | -84.39% |
| Dec 31, 2024 | 3.02% |
| Sep 30, 2024 | -71.70% |
| Jun 30, 2024 | 58.11% |
| Mar 31, 2024 | 39.74% |
| Dec 31, 2023 | -22.81% |
| Sep 30, 2023 | 81.08% |
| Jun 30, 2023 | -142.70% |
| Mar 31, 2023 | -26.42% |
API Access
Entrada Therapeutics Net Margin API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=net-margin&ticker=TRDA&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "net-margin", "ticker": "TRDA", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=net-margin&ticker=TRDA&period=max&api_key=YOUR_API_KEY");
const data = await res.json();